A in vivo assay for standardizing heparin preparations

Area of Science:

• Pharmacology
• Biomedical Assays
• Drug Efficacy Testing

Background:

• Current in vitro assays for heparin have limitations, necessitating the development of a more suitable in vivo method for routine use.
• The British Pharmacopoeia's existing in vitro heparin assay requires validation for its in vivo relevance.

Purpose of the Study:

• To develop and validate a novel, routine in vivo assay for assessing heparin's biological activity.
• To compare the efficacy of the new in vivo method against established in vitro methods, particularly those specified by the British Pharmacopoeia.

Main Methods:

• An in vivo assay was designed using four groups of five mice per heparin preparation, employing a "2 and 2 dose assay" intravenous injection protocol.
• The assay's speed was assessed, with a target of 3 to 4 hours for testing multiple heparin preparations against a standard.
• Accuracy and precision were evaluated against British Pharmacopoeia requirements, necessitating the combination of results from 3 to 4 independent assays.

Main Results:

• The described in vivo method demonstrated a rapid turnaround time, suitable for routine testing.
• Combining results from multiple assays achieved accuracy and precision levels that meet the British Pharmacopoeia's standards.
• Results from the in vivo method closely correlated with the British Pharmacopoeia's in vitro method for lung and mucosal heparin preparations.

Conclusions:

• The developed in vivo heparin assay is validated and suitable for routine use, providing reliable estimations of heparin's in vivo activity.
• The study validates the in vitro method of the British Pharmacopoeia by demonstrating its correlation with the new in vivo assay.
• This in vivo approach offers a reliable alternative for assessing heparin preparations, ensuring compliance with pharmacopoeial standards.